open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15
Get Citation

Suppressive thyroxine therapy of differentiated thyroid cancer in daily practice of a large cancer centre

Zbigniew Puch, Józef Roskosz, Beata Jurecka-Lubieniecka, Dorota Kula

open access

Vol 57, Supp. A (2006)
Original papers
Published online: 2006-09-25
Submitted: 2013-02-15

Abstract

Introduction: The study summarizes the results of an audit evaluating the realization of the suppressive TSH therapy in patients with differentiated thyroid cancer.
Material and methods: The evaluation was performed in 500 consecutive patients.
Results: In patients in whom remission was diagnosed < 5 years ago, in 70% subcomplete suppression was stated (TSH 0.1–0.3 mU/L) and complete suppression (TSH < 0.1 mU/L) was observed in 20%. Unexpectedly in patients in whom remission lasted > 5 years, complete suppression was observed in 60%. However, this last group was less numerous, thus, the majority of no evidence of disease patients exhibited subcomplete TSH suppression, while only 40% of patients with active disease had this goal realized.
Conclusions: 1. Iatrogenous hypothyroidism was well controlled in nearly all differentiated thyroid cancer patients.
2. The goal of L-thyroxine treatment, defined as TSH serum level < 0.4 mU/L was achieved in 90% of them without a significant risk of iatrogenous thyrotoxicosis.
3. Some overdosage of L-thyroxine was observed, especially in patients in whom remission lasted > 5 years. It this group of patients there is no reason to induce full suppression of TSH by L-thyroxine treatment.

Abstract

Introduction: The study summarizes the results of an audit evaluating the realization of the suppressive TSH therapy in patients with differentiated thyroid cancer.
Material and methods: The evaluation was performed in 500 consecutive patients.
Results: In patients in whom remission was diagnosed < 5 years ago, in 70% subcomplete suppression was stated (TSH 0.1–0.3 mU/L) and complete suppression (TSH < 0.1 mU/L) was observed in 20%. Unexpectedly in patients in whom remission lasted > 5 years, complete suppression was observed in 60%. However, this last group was less numerous, thus, the majority of no evidence of disease patients exhibited subcomplete TSH suppression, while only 40% of patients with active disease had this goal realized.
Conclusions: 1. Iatrogenous hypothyroidism was well controlled in nearly all differentiated thyroid cancer patients.
2. The goal of L-thyroxine treatment, defined as TSH serum level < 0.4 mU/L was achieved in 90% of them without a significant risk of iatrogenous thyrotoxicosis.
3. Some overdosage of L-thyroxine was observed, especially in patients in whom remission lasted > 5 years. It this group of patients there is no reason to induce full suppression of TSH by L-thyroxine treatment.
Get Citation

Keywords

TSH suppression; thyroid cancer; L-thyroxine

About this article
Title

Suppressive thyroxine therapy of differentiated thyroid cancer in daily practice of a large cancer centre

Journal

Endokrynologia Polska

Issue

Vol 57, Supp. A (2006)

Pages

59-64

Published online

2006-09-25

Keywords

TSH suppression
thyroid cancer
L-thyroxine

Authors

Zbigniew Puch
Józef Roskosz
Beata Jurecka-Lubieniecka
Dorota Kula

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl